Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization.

Williams KP, Allensworth JL, Ingram SM, Smith GR, Aldrich AJ, Sexton JZ, Devi GR. Quantitative high-throughput efficacy profiling of approved oncology drugs in inflammatory breast cancer models of acquired drug resistance and re-sensitization. Cancer Lett. 2013 Aug 28; 337(1):77-89.

View in: PubMed

subject areas

Antineoplastic Agents
Cell Line, Tumor
Cell Proliferation
Drug Resistance, Neoplasm
Drug Screening Assays, Antitumor
Female
High-Throughput Screening Assays
Humans
Quinazolines
X-Linked Inhibitor of Apoptosis Protein

authors with profiles

Kevin Williams

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support